Genzyme (NASDAQ: GENZ) reported a Phase II trial of its leukemia drug Campath (monoclonal antibody targeting CD52) showed superiority at treating multiple sclerosis over Merck’s (NYSE: MRK) Rebif (Interferon beta-1a).
Showing posts with label XX CD52. Show all posts
Showing posts with label XX CD52. Show all posts
Monday, October 15, 2007
Merck NEWS
Genzyme (NASDAQ: GENZ) reported a Phase II trial of its leukemia drug Campath (monoclonal antibody targeting CD52) showed superiority at treating multiple sclerosis over Merck’s (NYSE: MRK) Rebif (Interferon beta-1a).
Subscribe to:
Posts (Atom)
